Adds GLP-1 drug details and CEO comment throughout on Mounjaro
By Nqobile Dludla
JOHANNESBURG, March 3 (Reuters) - Aspen Pharmacare APNJ.J posted a 5% rise in half-year earnings on Monday and said it expects double-digit revenue and core profit growth in its commercial pharmaceuticals unit in the full year, benefiting from its Latin American portfolio and the roll-out of its weight-loss drug Mounjaro.
Its shares closed 11.7% stronger at 182 rand.
The South Africa-based pharmaceutical company is betting big on contracts for a class of medicines known as GLP-1 analogues for diabetes and weight loss.
It has an agreement with Eli Lilly LLY.N to sell, promote and distribute the American drugmaker's pharmaceutical portfolio in Sub-Saharan Africa, including Mounjaro in South Africa, which became available in late December.
In 2023, it also bought the commercialisation rights and related intellectual property for a portfolio of products in Latin America from Canonsburg, Pennsylvania-based Viatris VTRS.O.
These businesses helped boost revenue growth in the group's commercial pharmaceuticals business by 13% in constant currency terms to 16.1 billion rand in the six months to December 31.
Normalised earnings before interest, tax, depreciation and amortisation (EBITDA) from commercial pharmaceuticals grew 13%.
Aspen, which also has a presence in Asia, the Middle East, Africa, Australasia and Europe, said the double-digit forecast was in constant currency terms.
The company recorded normalised headline earnings per share $(HEPS)$ of 724.2 South African cents. Group revenue grew by 4% to 21.9 billion rand, with EBITDA up 12% at 5.8 billion rand.
CEO Stephen Saad told Reuters that the company is seeing increased demand for Mounjaro. "Before we even launched, it had (a) nearly 20% (share) of the (South African) market," he said, based on generated scripts.
Aspen has also applied to broaden the reach of the product to weight management, Saad said, adding that it is registering Mounjaro in some Sub-Saharan African markets.
($1 = 18.6454 rand)
(Reporting by Nqobile Dludla, Editing by Louise Heavens, Sharon Singleton and Jan Harvey)
((nqobile.dludla@thomsonreuters.com; +27103461066;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.